iOS
Android
Facebook
WhatsApp
Twitter
Reglutide (Semaglutide 1.34 mg/ml) is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for the treatment of type 2 diabetes mellitus and chronic weight management. It is administered via subcutaneous injection. Diabetes Management: Improves glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Cardiovascular Risk Reduction: Reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. Weight Management: Supports chronic weight management in adults with a BMI of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity.
Brand Name: Reglutide SC Injection Active Ingredient: Semaglutide 1.34 mg/ml Manufacturer: Beximco Pharmaceuticals Ltd Formulation: 3 ml cartridge with device
Diabetes: Start with 0.25 mg once weekly, increase to 0.5 mg after 4 weeks, and up to 1 mg weekly for further control. Obesity: Start with 0.25 mg once weekly for 4 weeks, increase to 0.5 mg, and eventually to 2.4 mg weekly. Adjust as tolerated. Administration: Inject subcutaneously in the abdomen, thigh, or upper arm. Do not inject intravenously or intramuscularly.Â
KES 39,000.00
Delivery within 4 hours on all orders placed between 8:00 AM & 8:00 PM
